home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

The Importance of Method Validation for BioPharmaceuticals: FREE WEBINAR

 
  January 18, 2018  
     
 
CfPA-The Center for Professional Advancement, FREE WEBINAR
January 24, 2018 at 11:00 a.m.–11:30 a.m. (ET)


Who Should Attend?
This informational webinar will provide insight to biopharmaceutical personnel on the importance of analytical method validation. Different method types and techniques will be discussed.

It will be valuable to the following professionals:
  • Quality Control, Quality Assurance
  • Analytical Scientist 
  • Research Associates
  • Engineers and Administrators working in analytical development, Product Development, Manufacturing, Validation, Formulation, and Pre-formulation groups, though any inquiring minds within this industry are welcome to join

Course Description
This 30-minute, informational webinar is intended to describe the importance of validation of commonly used methods for biopharmaceuticals.

  • Method types that will be discussed during course are UV-VIS (content), SEC
     purity and potency ELISA. 

  • For each method will discuss 
     – Reportable data from method
     – What parameters should be tested during method validation 
     – How method validation effects product quality

Can’t attend LIVE? Register anyway and we’ll send you a link to the webinar recording afterwards.

For complete coverage of this subject check our website for: 
Biopharmaceutical Analytics: Regulations and Validations
March 8-9, 2018 | New Brunswick, NJ | Attend In Person or Virtually
 
 
Organized by: CfPA-The Center for Professional Advancement
Invited Speakers:
   Rachel Monsef, Consultant to the pharmaceutical and biopharmaceutical industries

Rachel Monsef is a consultant to the biopharmaceutical industry for analytical and quality control. She has 17 years’ experience working with many types of assay for all stages of drug development. She has been responsible for method development, method qualification, method validations, assay transfer, characterization work, and stability studies. She has also worked with manufacturing groups to develop and perform assays to support their efforts. She has previously worked for Seattle Genetics and Alder Biopharmaceuticals and is currently consulting for Alder Biopharmaceuticals. 

 


 
Deadline for Abstracts: n/a
 
Registration: Please click here for registration information.
E-mail: jmorbit@cfpa.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.